BLA 125370/S-073
BLA 761043/S-013

SUPPLEMENT APPROVAL

Human Genome Sciences, Inc.
1250 South Collegeville Road
Collegeville, PA 19426

Attention: Wendy Valinski, MS
Director, Global Regulatory Affairs

Dear Ms. Valinski:

Please refer to your supplemental biologics license applications (sBLA) 125370/S-073, dated June 16, 2020 for Benlysta (belimumab) 120 mg and 400 mg lyophilized powder for intravenous injection and 761043/S-013 dated June 17, 2020 for Benlysta (belimumab) 200 mg/mL solution for subcutaneous injection and your amendments, submitted under section 351(a) of the Public Health Service Act.

The Prior Approval supplemental biologics applications (sBLA) provides for use of Benlysta in adult patients with active lupus nephritis who are receiving standard therapy.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,[1] that is identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

We acknowledge your December 4, 2020, submission to BLA 761043/S-013 containing final printed carton labeling.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study(ies) requirement for ages 0 to 5 years because necessary studies are impossible or highly impractical. This is because the number of pediatric patients is so small or is geographically dispersed.

We are deferring submission of your pediatric study(ies) for ages 5 to 17 years for this application because this product is ready for approval for use in adults and the pediatric study (i.e. PK-based extrapolation from adult LN study) have not been completed.

Your deferred pediatric study(ies) required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act are required postmarketing study(ies). The status of this postmarketing study(ies) must be reported annually according to 21 CFR 601.28 and section 505B(a)(4)(B) of the Federal Food, Drug, and Cosmetic Act. This/These required study(ies) is/are listed below.

3994-1 Provide an assessment of intravenous belimumab for the treatment of patients ages 5 to less than 18 years of age with lupus nephritis who are receiving standard therapy.

Final Report Submission: 11/2021

3994-2 Provide an assessment of subcutaneous belimumab for the treatment of patients ages 5 to less than 18 years of age with lupus nephritis who are receiving standard therapy.

Final Report Submission: 11/2023

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.[3]

Submit the protocol(s) to your IND 9970, with a cross-reference letter to these BLA's. Reports of these required pediatric postmarketing studies must be submitted as a BLA or as a supplement to your approved BLA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

FULFILLMENT OF POSTMARKETING REQUIREMENT(S)/COMMITMENT(S)

We have received your submission dated April 7, 2020, containing the final study report from study BEL114054/C1121 to fulfill the following postmarketing commitment listed in the March 9, 2011 approval letter for BLA 125370:

2661-6 Conduct a randomized, controlled clinical trial in patients with lupus nephritis to evaluate the efficacy and safety of Benlysta (belimumab).

We have reviewed your submission and conclude that the above commitment was fulfilled.

We remind you that there are postmarketing requirements and postmarketing commitments listed in the March 9, 2011, approval letter that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

[3] See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019).* https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.[4]

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.[5] Information and Instructions for completing the form can be found at FDA.gov.[6]

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Susan Rhee, Regulatory Project Manager, at 301-796-2402.

Sincerely,

{See appended electronic signature page}

Nikolay Nikolov, MD
Director
Division of Rheumatology and Transplant Medicine
Office of Immunology and Inflammation
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Medication Guide
  - Instructions for Use
- Carton Labeling

[4] For the most recent version of a guidance, check the FDA guidance web page athttps://www.fda.gov/media/128163/download.
[5] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
[6] http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NIKOLAY P NIKOLOV
12/16/2020 06:50:19 PM